Related Experiment Video
Updated: May 26, 2026
09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Does Apolipoprotein E genotype affect cardiovascular risk in subjects with acromegaly?
Vildan Bozok Cetintas1, Ayhan Zengi, Asli Tetik
1Department of Medical Biology, Ege University Medical School, 35100 Bornova, Izmir, Turkey. vildanbcetintas@gmail.com
Endocrine
|December 28, 2011
Summary
The Apolipoprotein E4 allele is more common in acromegaly patients, increasing cardiovascular risk. The Apolipoprotein E2 genotype is linked to obesity and inflammation markers in acromegaly.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Genetics
Background:
- Acromegaly, caused by excess growth hormone, significantly elevates mortality risk from cardiovascular diseases.
- Cardiovascular complications are a major concern in acromegaly patients.
- The role of Apolipoprotein E (Apo E) genotype in acromegaly's cardiovascular risk is not well-established.
Purpose of the Study:
- To investigate the association between Apolipoprotein E (Apo E) genotype and cardiovascular complications in acromegaly.
- To determine if specific Apo E genotypes contribute to increased cardiovascular risk in acromegaly patients.
Main Methods:
- A case-control study involving 102 acromegaly patients and 200 healthy controls.
- Genomic DNA isolation from peripheral blood leukocytes.
- Apolipoprotein E (Apo E) genotype assessment using real-time PCR and melting temperature analyses.
Main Results:
- The Apolipoprotein E4 allele was found at a significantly higher frequency in acromegaly patients compared to controls (P=0.032).
- Subjects with the Apolipoprotein E2 allele exhibited increased body mass index (P=0.004), waist circumference (P=0.001), C-reactive protein (CRP) (P<0.001), and left-side carotid intima media thickness (P=0.025).
Conclusions:
- The Apolipoprotein E4 allele may be a risk factor for cardiovascular complications in acromegaly.
- The Apolipoprotein E2 genotype is associated with obesity and inflammation markers, suggesting a potential contribution to cardiovascular risk in acromegaly.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...